Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.85 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
60,207.93 -2,068.31 (-3.32%) CMC Crypto 200
1,298.04 -36.88 (-2.76%)
Sandoz Group AG (SDZ.SW)
| Previous close | 32.49 |
| Open | 32.52 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 32.28 - 33.10 |
| 52-week range | 22.70 - 33.16 |
| Volume | |
| Avg. volume | 1,250,902 |
| Market cap | 14.115B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 205.19 |
| EPS (TTM) | 0.16 |
| Earnings date | N/A |
| Forward dividend & yield | 0.45 (1.39%) |
| Ex-dividend date | 03 May 2024 |
| 1y target est | 37.40 |
GlobeNewswireFDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel,
GlobeNewswireImproving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
GlobeNewswireSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
